Copenhagen, 2011-11-14 08:23 CET (GLOBE NEWSWIRE) --

Performance for the period (unaudited)
(Comparative figures for the same period of last year are given in brackets.
Sales growth is measured in local currencies)

Growth in revenues and earnings in the first nine months was better than
expected, primarily due to higher partner revenues:

-- Total revenue increased by 14% to DKK 1,770 million (1,571).
-- Revenues from partners totalled DKK 233 million (18).
-- Vaccine sales grew by 6%.
-- Sales growth was driven in particular by the developments in France, Spain,
the Netherlands and North America.
-- Operating profit (EBITDA) increased by 77% to DKK 361 million (204).
-- Net profit was DKK 181 million (88).
-- Free cash flow was DKK 214 million (an outflow of 184), while cash and cash
equivalents totalled DKK 403 million.

The positive development in ALK's business has continued in recent months:

-- Merck has recently announced that they expect to file registration
applications for GRAZAX® and Ragweed AIT with the US health authorities,
the FDA, in 2013.
-- Data from the successfully completed clinical Phase III studies with the
new ragweed allergy immunotherapy tablet (AIT) were presented by ALK's
partner Merck at the 2011 Annual Meeting of the American College of
Allergy, Asthma & Immunology (ACAAI) in Boston, USA. Both studies met their
primary efficacy endpoints, and the efficacy results were robust and
consistent between the two studies.
-- ALK's partner Torii initiated the clinical development of MITIZAX®, the new
tablet (AIT) against house dust mite induced hay fever and asthma, in
Japan. The initiation released a milestone payment to ALK.
-- Based on the positive business progress, ALK has decided to accelerate the
development of MITIZAX® in Europe and has initiated an additional clinical
Phase III study. ALK is now conducting two parallel Phase III studies
involving up to 1,700 patients in 17 European countries.
-- At the end of Q3, ALK launched Jext® in Europe. The new, improved
adrenaline pen for emergency treatment of severe acute allergic reactions
has initially been well received and the launch is progressing as planned.

Outlook for the 2011 financial year unchanged
For the 2011 financial year, ALK continues to anticipate growth in sales of
allergy vaccines of around 5% measured in local currencies. Revenue is still
expected to exceed DKK 2.3 billion. Operating profit (EBITDA) is still expected
to total more than DKK 400 million (287). ALK's financial outlook for 2011 has
been adjusted upwards twice since the beginning of the year as a consequence of
milestone payments from licence partners which were triggered earlier than
expected. The earnings in 2011 are extraordinarily high, in particular due to
the strategic partnership with Torii in Japan.

Hørsholm, 14 November 2011

ALK-Abelló A/S



Contact:
Jens Bager, President and CEO, tel. +45 4574 7576.
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

ALK is holding a conference call for analysts and investors today at 11.00 a.m.
(CET) at which Jens Bager, President and CEO, and Flemming Pedersen, CFO, will
review the results. Participants in the conference call are kindly requested to
call in before 10.55 a.m. (CET). Danish participants should call in on tel. +45
7014 0453, and international participants should call in on tel. +44 207 108 63
03.

The conference call will also be webcast on our website,
www.alk-abello.com/investor, where the related presentation will be available
shortly before the conference call begins.

FM_21_11UK_14112011.pdf